Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma

2016304 citationsJournal Article

Authors

Sofie Wilgenhof · Universitair Ziekenhuis Brussel

Jurgen Corthals · Universitair Ziekenhuis Brussel

Carlo Heirman · Universitair Ziekenhuis Brussel

Nicolas van Baren · Universitair Ziekenhuis Brussel

Sophie Lucas · Universitair Ziekenhuis Brussel

Pia Kvistborg · Universitair Ziekenhuis Brussel

Kris Thielemans

Abstract

The combination of TriMixDC-MEL and ipilimumab is tolerable and results in an encouraging rate of highly durable tumor responses in patients with pretreated advanced melanoma.

Topics & Keywords

Immunotherapy and Immune Responses CAR-T cell therapy research RNA Interference and Gene Delivery

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 34, Issue 12, pp. 1330-1338

DOI: 10.1200/jco.2015.63.4121

Field-Weighted Citation Impact: 14.79